mProX™ Human TACSTD2 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TACSTD2, also known as Trop-2, is a transmembrane glycoprotein that has been studied in various contexts. In the context of polycystic ovary syndrome (PCOS), TACSTD2 has been identified as a potential biomarker for diagnosis and treatment. It has been found to be differentially methylated and expressed in ovarian granulosa cells of PCOS patients compared to healthy controls. TACSTD2 has also been implicated in early luminal-like breast cancer, where it is highly expressed. In systemic lupus erythematosus (SLE), TACSTD2 has been identified as one of the differentially expressed genes associated with disease severity. Additionally, TACSTD2 has been studied in high-grade serous ovarian carcinoma (HGSOC), where it has been identified as a specific protein marker in cancer cell-derived extracellular vesicles. Furthermore, TACSTD2 has been investigated in the context of rare diseases, such as gelatinous droplike corneal dystrophy (GDLD), where modulation of the UDP-glucose glycoprotein glucosyl-transferase (UGGT) pathway, which involves TACSTD2, has shown potential as a therapeutic strategy. Overall, TACSTD2 has been implicated in various diseases and has potential as a diagnostic and therapeutic target.